glyburide has been researched along with Disease Exacerbation in 15 studies
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide
glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with treatment-naive type 2 diabetes (N = 16) were treated with insulin and metformin for a 3-month lead-in period, then assigned triple oral therapy (metformin, glyburide, and pioglitazone) or continued treatment with insulin and metformin." | 2.77 | Effect of insulin versus triple oral therapy on the progression of hepatic steatosis in type 2 diabetes. ( Duong, J; Leonard, D; Lingvay, I; Roe, ED; Szczepaniak, LS, 2012) |
| "Type 2 diabetes mellitus is the consequence of both insulin resistance and impaired insulin secretion." | 1.32 | Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context. ( Abrahamson, MJ, 2004) |
| "Cyst growth in ADPKD is driven by cell proliferation and Cl(-) and fluid secretion." | 1.31 | Sulfonylurea-sensitive K(+) transport is involved in Cl(-) secretion and cyst trowth by cultured ADPKD cells. ( Eppler, JW; Gover, T; Grantham, JJ; Maser, R; Sullivan, LP; Wallace, DP; Welling, PA; Yamaguchi, T, 2002) |
| "Mibefradil is a novel calcium channel blocker with activity at both L-type and T-type calcium channels." | 1.30 | Mibefradil, a T-type and L-type calcium channel blocker, limits infarct size through a glibenclamide-sensitive mechanism. ( Baxter, GF; Gadgil, S; Mocanu, MM; Yellon, DM, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 9 (60.00) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bolanle, IO | 1 |
| Omogbai, EKI | 1 |
| Bafor, EE | 1 |
| Popovich, PG | 1 |
| Lemeshow, S | 1 |
| Gensel, JC | 1 |
| Tovar, CA | 1 |
| Simard, JM | 1 |
| Gerzanich, V | 1 |
| Lingvay, I | 1 |
| Roe, ED | 1 |
| Duong, J | 1 |
| Leonard, D | 1 |
| Szczepaniak, LS | 1 |
| Brooks-Worrell, BM | 1 |
| Palmer, JP | 1 |
| Viberti, G | 2 |
| Kahn, SE | 2 |
| Greene, DA | 1 |
| Herman, WH | 2 |
| Zinman, B | 2 |
| Holman, RR | 2 |
| Haffner, SM | 2 |
| Levy, D | 1 |
| Lachin, JM | 2 |
| Berry, RA | 1 |
| Heise, MA | 2 |
| Jones, NP | 1 |
| Freed, MI | 1 |
| Sullivan, LP | 1 |
| Wallace, DP | 1 |
| Gover, T | 1 |
| Welling, PA | 1 |
| Yamaguchi, T | 1 |
| Maser, R | 1 |
| Eppler, JW | 1 |
| Grantham, JJ | 1 |
| Abrahamson, MJ | 1 |
| Riddle, MC | 1 |
| Charpentier, G | 1 |
| Riveline, JP | 1 |
| Dardari, D | 1 |
| Varroud-Vial, M | 1 |
| Wardle, EN | 1 |
| Einecke, D | 1 |
| Kravitz, BG | 1 |
| Yu, D | 1 |
| Aftring, RP | 1 |
| Mocanu, MM | 1 |
| Gadgil, S | 1 |
| Yellon, DM | 1 |
| Baxter, GF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Rosiglitazone Intervention Study in Patients With Type 1.5 Diabetes[NCT00194896] | 64 participants (Actual) | Interventional | 2000-02-29 | Completed | |||
| A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients With Drug-Naive, Recently Diagnosed [NCT00279045] | Phase 3 | 4,426 participants (Actual) | Interventional | 2000-01-03 | Completed | ||
| The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study[NCT03222206] | Phase 4 | 34 participants (Actual) | Interventional | 2017-11-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants positive for T cell reactivity to islet proteins at 36 months. (NCT00194896)
Timeframe: 36 months
| Intervention | participants (Number) |
|---|---|
| Rosiglitazone Autoantibody Positive | 1 |
| Rosiglitazone Autoantibody Negative | 2 |
| Glyburide Autoantibody Positive | 2 |
| Glyburide Autoantibody Negative | 3 |
Changes in beta cell function assessed by fasting and stimulated C-peptide measured at 36 months. (NCT00194896)
Timeframe: 36 months
| Intervention | ng per ml (Mean) | |
|---|---|---|
| Fasting C-peptide | Glucagon Stimulated C-peptide | |
| Glyburide Autoantibody Negative | 0.3 | 0.3 |
| Glyburide Autoantibody Positive | 0.1 | 3.1 |
| Rosiglitazone Autoantibody Negative | -1.4 | -2.8 |
| Rosiglitazone Autoantibody Positive | -0.4 | -0.6 |
2 reviews available for glyburide and Disease Exacerbation
| Article | Year |
|---|---|
Timely initiation of basal insulin.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy, Combination | 2004 |
Should postprandial hyperglycaemia in prediabetic and type 2 diabetic patients be treated?
Topics: Acarbose; Adult; Aged; Aged, 80 and over; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitu | 2006 |
4 trials available for glyburide and Disease Exacerbation
| Article | Year |
|---|---|
Effect of insulin versus triple oral therapy on the progression of hepatic steatosis in type 2 diabetes.
Topics: Administration, Oral; Adult; Aged; Diabetes Mellitus, Type 2; Disease Progression; Fatty Liver; Fema | 2012 |
Attenuation of islet-specific T cell responses is associated with C-peptide improvement in autoimmune type 2 diabetes patients.
Topics: Adult; Aged; Autoantibodies; Autoimmunity; C-Peptide; Cells, Cultured; Diabetes Mellitus, Type 2; Di | 2013 |
A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
Topics: Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Gly | 2002 |
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
Topics: Age of Onset; Aged; Diabetes Mellitus, Type 2; Disease Progression; Female; Fractures, Bone; Glyburi | 2008 |
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
Topics: Age of Onset; Aged; Diabetes Mellitus, Type 2; Disease Progression; Female; Fractures, Bone; Glyburi | 2008 |
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
Topics: Age of Onset; Aged; Diabetes Mellitus, Type 2; Disease Progression; Female; Fractures, Bone; Glyburi | 2008 |
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
Topics: Age of Onset; Aged; Diabetes Mellitus, Type 2; Disease Progression; Female; Fractures, Bone; Glyburi | 2008 |
9 other studies available for glyburide and Disease Exacerbation
| Article | Year |
|---|---|
Effects of amlodipine and valsartan on glibenclamide-treated streptozotocin-induced diabetic rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Biomarkers; Blood Glucose; Diabetes Mellitus, Experime | 2018 |
Independent evaluation of the effects of glibenclamide on reducing progressive hemorrhagic necrosis after cervical spinal cord injury.
Topics: Animals; Cervical Vertebrae; Disease Progression; Drug Evaluation, Preclinical; Female; Glyburide; H | 2012 |
When replication teaches more than the original experiment--the saga of the unknown unknown.
Topics: Animals; Disease Progression; Female; Glyburide; Hematoma, Epidural, Spinal; Spinal Cord Injuries | 2012 |
Sulfonylurea-sensitive K(+) transport is involved in Cl(-) secretion and cyst trowth by cultured ADPKD cells.
Topics: Barium; Cell Division; Cells, Cultured; Charybdotoxin; Chlorides; Disease Progression; Glyburide; Hu | 2002 |
Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context.
Topics: Antihypertensive Agents; Blood Glucose; Blood Glucose Self-Monitoring; Carbamates; Diabetes Mellitus | 2004 |
Up-date on renal fibrosis: a time for action.
Topics: Cell Proliferation; Disease Progression; Extracellular Matrix; Fibrosis; Glyburide; Humans; Hypoglyc | 2007 |
[ADOPT study. Glitazone controls diabetes progression].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Glyburide; Glycated Hemoglobin; Human | 2007 |
[ADOPT study: Reevaluation of antidiabetic drugs. Control of diabetes].
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Disease Progression; Glyburide; | 2007 |
Mibefradil, a T-type and L-type calcium channel blocker, limits infarct size through a glibenclamide-sensitive mechanism.
Topics: Animals; Benzimidazoles; Calcium Channel Blockers; Disease Progression; Enzyme Activation; Glyburide | 1999 |